Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer

Dose dense chemotherapy, which is the term for Adriamycin and Cyclophosphamide (AC) followed by Taxol chemotherapy given every two weeks, is the standard chemotherapy for the treatment of ER+ or PR+ breast cancer. In this trial, the standard chemotherapy is being combined with bevacizumab. Bevacizumab is an antibody which works differently from the way other chemotherapy drugs work. Bevacizumab slows or stops cell growth in cancerous tumors by decreasing the blood supply to the tumors by binding to a substance found on cancer cells called VEGF (vascular endothelial growth factor). Bevacizumab is approved by the FDA for the treatment of colorectal cancer and lung cancer. However, it is not approved for the treatment of breast cancer. Another goal of this research is to determine whether we can develop a way to identify tumors that will respond well to this study treatment.

Study Overview

• Status: Completed
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Paclitaxel; Drug: Bevacizumab

Detailed Description

• To prepare for the surgery that will occur at the end of the study treatment, a small "clip" will be placed into the tumor area so that the surgeon can locate the site of the tumor at the time of surgery. This is a standard procedure for breast cancer.
• During the clip placement, a needle will be inserted into the tumor to measure interstitial fluid pressure (IFP measurement). IFP is done for research purposes to help understand how the tumor responds to the study treatment.
• Study treatment will begin with one dose of bevacizumab alone, followed two weeks later by chemotherapy and bevacizumab in eight two-week cycles. The study treatment will be given intravenously in the clinic.
• After the first dose of bevacizumab and prior to starting chemotherapy, a needle biopsy of the breast tumor will be performed for research purposes. A second measurement of IFP will also be done at this time.
• During the treatment period, tests and procedures will be performed at specified intervals and include the following: research MRI, physical exams, blood tests, urine tests, EKG, and MUGA or ECHO.
• Surgery to remove the tumor will occur no less than four weeks after the last dose of Paclitaxel.

• Study Type: Interventional
• Enrollment (Actual): 104
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Dana-Farber Cancer Institute
    • Boston, Massachusetts, United States, 02114
      • Massachusetts General Hospital
    • Boston, Massachusetts, United States, 02130
      • Dana-Farber at Faulkner Hospital
  • New Hampshire
    • Hooksett, New Hampshire, United States, 03106
      • New Hampshire Oncology-Hematology PA

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Documented primary invasive breast cancer by histologic assessment
• Tumors must express estrogen (ER) and/or progesterone receptors (PR) by standard immunohistochemical methods. Tumors must be negative for HER2. There must be sufficient sample for further protocol-specified immunohistochemical analysis
• Patients must have high risk ER+ or PR+ breast cancer as defined by criteria listed in protocol
• 18 year of age or older
• Performance status of 0 or 1 by ECOG criteria
• Use of an effective means of contraception in subjects of childbearing potential
• Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to starting therapy.
• Patients taking exogenous sex-steroid hormone treatments for any reason at the time of diagnosis must discontinue all hormonal treatments at least 2 weeks prior to enrollment
• Patients must have preoperative treatment within 60 days of initial diagnosis of breast cancer
• No other malignancy that requires on-going treatment
• Normal organ function as outlined in the protocol

Exclusion Criteria:

• Prior cytotoxic chemotherapy or radiation for the current breast cancer
• Patients with inflammatory breast cancer
• HER2 positive disease defined as HER2-amplified by FISH or IHC 3+. HER2 2+ must be negative by FISH
• Known metastatic (Stage IV) disease
• Other investigational agents within 4 weeks prior to the start of study treatment
• Life expectancy of less than 6 months
• Peripheral neuropathy greater than or equal to grade 2
• Inadequately controlled hypertension
• Any prior history of hypertensive crisis or hypertensive encephalopathy
• NYHA grade II or greater congestive heart failure
• History of prior myocardial infarction
• History of unstable angina within 12 months prior to study enrollment
• Any history of stroke or transient ischemic attack at any time
• Known CNS disease
• Significant vascular disease
• Symptomatic peripheral vascular disease
• Evidence of significant bleeding within 6 months of study; any serious non-healing wound, skin ulcers, or bone fracture; any abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months; any major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during course of study.
• Known HIV positive
• Unwilling to undergo pretreatment biopsy and consent to acquisition of archival tissue
• Pregnant of lactating
• Known hypersensitivity to any component of bevacizumab

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: HR+, HER2-; Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.	Drug: Doxorubicin; Standard chemotherapy regimen; Other Names: Adriamycin; Drug: Cyclophosphamide; Standard chemotherapy regimen; Other Names: Cytoxan; Drug: Paclitaxel; Standard chemotherapy regimen; Other Names: Taxol; Drug: Bevacizumab; One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.; Other Names: Avastin
Active Comparator: Triple Negative Breast Cancer Cohort; Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.	Drug: Doxorubicin; Standard chemotherapy regimen; Other Names: Adriamycin; Drug: Cyclophosphamide; Standard chemotherapy regimen; Other Names: Cytoxan; Drug: Paclitaxel; Standard chemotherapy regimen; Other Names: Taxol; Drug: Bevacizumab; One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.; Other Names: Avastin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population.	Pathological Complete response is defined as complete disappearance of invasive tumor in the breast at the time of surgery	3 Years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Decrease in Interstitial Fluid Pressure.	To determine if bevacizumab monotherapy results in a decrease in interstitial fluid pressure	3 years

Collaborators and Investigators

• Sponsor: Ian E. Krop, MD, PhD
• Collaborators: Massachusetts General Hospital; Genentech, Inc.; Brigham and Women's Hospital; New Hampshire Oncology-Hematology PA
• Investigators: Principal Investigator: Ian Krop, MD, PhD, Dana-Farber Cancer Institute

Study record dates

Study Major Dates

• Study Start: October 1, 2007
• Primary Completion (Actual): October 1, 2011
• Study Completion (Actual): December 1, 2012

Study Registration Dates

• First Submitted: October 17, 2007
• First Submitted That Met QC Criteria: October 17, 2007
• First Posted (Estimate): October 18, 2007

Study Record Updates

• Last Update Posted (Actual): May 18, 2021
• Last Update Submitted That Met QC Criteria: April 26, 2021
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Keywords: ER positive; PR positive
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antineoplastic Agents, Immunological; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Antibiotics, Antineoplastic; Cyclophosphamide; Paclitaxel; Bevacizumab; Doxorubicin
• Other Study ID Numbers: 07-130